Proteon logo     Print Page | Close Window

SEC Filings

S-1
PROTEON THERAPEUTICS INC filed this Form S-1 on 09/16/2014
Entire Document
 

Table of Contents


MANAGEMENT

Executive Officers and Directors

        The following table sets forth the names, ages and positions of the directors and executive officers of Proteon as of August 31, 2014.

Name
  Age   Position(s)

Timothy P. Noyes

    52   President, Chief Executive Officer and Director

Steven K. Burke, M.D. 

    54   Senior Vice President and Chief Medical Officer

George A. Eldridge

    51   Senior Vice President, Chief Financial Officer, Treasurer and Secretary

Daniel P. Gottlieb

    44   Vice President, Marketing and Business Development
           

Non-Employee Directors

         

Hubert Birner, Ph.D.(1)(2)(3)

    48   Director

Garen Bohlin(2)

    67   Director

Todd Foley*

    42   Director

F. Nicholas Franano, M.D.*

    47   Director

John G. Freund, M.D. 

    60   Director

Tim Haines(1)(3)

    56   Director

Dmitry Kobyzev, Ph.D.(2)(3)

    29   Director

Brendan M. O'Leary, Ph.D.(1)(2)

    42   Director

Gregory D. Phelps(1)

    65   Chairman of the Board of Directors

(1)
Member of the Compensation Committee.

(2)
Member of the Audit Committee.

(3)
Member of the Nominating and Corporate Governance Committee.

*
We expect that, effective upon the completion of this offering, Mr. Foley and Dr. Franano will resign from our board of directors and we will reduce the size of our board of directors by two from 10 to eight.

Executive Officers

        Timothy P. Noyes joined Proteon in April 2006 as our President and Chief Executive Officer and has also been a member of our board of directors since joining Proteon. From 2002 to 2006, Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals from 1996 to 2001, prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002, he held the positions of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School. We believe Mr. Noyes is qualified to serve as a member of our board of directors because of his role with us and his extensive operational knowledge of, and executive level management experience in, the biopharmaceutical industry.

        Steven K. Burke, M.D., joined Proteon in August 2006 as our Senior Vice President and Chief Medical Officer. Prior to joining Proteon, Dr. Burke held various roles at Genzyme Corporation from 2000 to 2006, where he served most recently as Senior Vice President of Medical and Regulatory Affairs and Vice President of Clinical Research. From 1994 to 2000, Dr. Burke held roles at GelTex Pharmaceuticals, including Vice President of Clinical Research and Medical Director, and before that he held positions at

113